1 Report Introduction

2 Microscopic Polyangiitis (MPA) Market Overview at a Glance
2.1 Market Share (%) Distribution of Microscopic Polyangiitis (MPA) in 2018
2.2 Market Share (%) Distribution of Microscopic Polyangiitis (MPA) in 2030

3 Executive Summary of Microscopic Polyangiitis (MPA)

4 Disease Background and Overview
4.1 Introduction
4.2 Causes
4.3 Symptoms of MPA
4.4 Clinical Manifestations of MPA
4.5 Pathogenesis of MPA
4.6 Biomarkers of MPA
4.7 Genetic Analysis
4.8 Diagnosis of MPA
4.8.1 Diagnostic Algorithm of Vasculitis
4.8.2 Diagnostic Guidelines of MPA
4.8.2.1 Revised 2017 International Consensus on Testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis
4.8.2.2 EULAR/ERA-EDTA Recommendations for the Management of ANCA-associated Vasculitis
4.8.2.3 SICVE guidelines: Systemic vasculitis
4.9 Treatment and Management
4.9.1 General approach used in the treatment of MPA
4.9.2 Therapeutic agents used in the treatment of MPA
4.9.3 Adjunctive therapies for refractory disease
4.9.4 Treatment algorithm for AAV
4.9.5 Guidelines for the treatment of MPA
4.9.5.1 European League against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
4.9.5.2 SICVE guidelines: Systemic vasculitis
5 Epidemiology and Patient Population
5.1 Key Findings
5.2 Methodology of Epidemiology
5.3 Total Incident Cases of Microscopic polyangiitis (MPA) in the 7MM
5.4 Epidemiology of Microscopic polyangiitis (MPA)
5.5 The United States
5.5.1 Total Incident Cases of Microscopic polyangiitis (MPA) in the US
5.5.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the US
5.5.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the US
5.6 EU5
5.6.1 Germany
5.6.1.1 Total Incident Cases of Microscopic polyangiitis (MPA) in Germany
5.6.1.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Germany
5.6.1.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Germany
5.6.2 France
5.6.2.1 Total Incident Cases of Microscopic polyangiitis (MPA) in France
5.6.2.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in France
5.6.2.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in France
5.6.3 Italy
5.6.3.1 Total Incident Cases of Microscopic polyangiitis (MPA) in Italy
5.6.3.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Italy
5.6.3.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Italy
5.6.4 Spain
5.6.4.1 Total Incident Cases of Microscopic polyangiitis (MPA) in Spain
5.6.4.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain
5.6.4.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain
5.6.5 The United Kingdom
5.6.5.1 Total Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom
5.6.5.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom
5.6.5.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom
5.7 Japan
5.7.1 Total Incident Cases of Microscopic polyangiitis (MPA) in Japan
5.7.2 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan
5.7.3 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan

6 Patient Journey

7 Organizations contributing toward Microscopic Polyangiitis (MPA)

8 Marketed Therapies
8.1 Rituxan/MabThera (rituximab): Genentech, Inc. (F. Hoffmann-La Roche Ltd)/Zenyaku Kogyo
8.1.1 Product Description
8.1.2 Regulatory Milestones
8.1.3 Other Developmental Activities
8.1.4 Clinical Development
8.1.5 Clinical Trials Information
8.1.6 Safety and Efficacy of Rituximab
8.1.7 Product Profile

9 Emerging Therapies
9.1 Key Cross Competition
9.2 Vilobelimab (IFX-1, CaCP290): InflaRx GmbH
9.2.1 Drug Description
9.2.2 Other Developmental Activities
9.2.3 Clinical Development
9.2.4 Clinical Trials Information
9.2.5 Product Profile
9.3 Vynpenta (Avacopan, CCX168): ChemoCentryx/Kissei Pharmaceutical/Vifor Pharma
9.3.1 Drug Description
9.3.2 Other Developmental Activities
9.3.3 Clinical Development
9.3.4 Clinical Trials Information
9.3.5 Safety and Efficacy
9.3.6 Product Profile
9.4 Belimumab: GlaxoSmithKline
9.4.1 Drug Description
9.4.2 Clinical Development
9.4.3 Clinical Trials Information
9.4.4 Safety and Efficacy
9.4.5 Product Profile
9.5 GGS-MPA (Freeze-dried Sulfonated Human Immunoglobulin): Teijin Pharma
9.5.1 Drug Description
9.5.2 Other Developmental Activities
9.5.3 Clinical Development
9.5.4 Clinical Trials Information
9.5.5 Product Profile

10 Microscopic Polyangiitis (MPA): Seven Major Market Analysis
10.1 Key Findings
10.2 Methodology of Microscopic Polyangiitis (MPA) Market
10.3 Market Size of Microscopic polyangiitis in the 7MM
10.4 Market Size of Microscopic polyangiitis by Therapies
10.5 Key Market Forecast Assumptions

11 Seven Major Market Outlook
11.1 United States Market Size
11.1.1 Total Market Size of Microscopic polyangiitis in the United States
11.1.2 Market Size of Microscopic polyangiitis by Therapies in the United States
11.2 EU-5 Market Size
11.2.1 Germany
11.2.1.1 Total Market size of Microscopic polyangiitis in Germany
11.2.1.2 Market Size of Microscopic polyangiitis by Therapies in Germany
11.2.2 France
11.2.2.1 Total Market size of Microscopic polyangiitis in France
11.2.2.2 Market Size of Microscopic polyangiitis by Therapies in France
11.2.3 Italy
11.2.3.1 Total Market size of Microscopic polyangiitis in Italy
11.2.3.2 Market Size of Microscopic polyangiitis by Therapies in Italy
11.2.4 Spain
11.2.4.1 Total Market size of Microscopic polyangiitis in Spain
11.2.4.2 Market Size of Microscopic polyangiitis by Therapies in Spain
11.2.5 United Kingdom
11.2.5.1 Total Market size of Microscopic polyangiitis in the United Kingdom
11.2.5.2 Market Size of Microscopic polyangiitis by Therapies in the United Kingdom
11.3 Japan
11.3.1 Total Market size of Microscopic polyangiitis in Japan
11.3.2 Market Size of Microscopic polyangiitis by Therapies in Japan

12 KOL Views

13 Market Drivers

14 Market Barriers

15 SWOT Analysis

16 Unmet Needs

17 Reimbursement and Market Access

18 Appendix
18.1 Bibliography
18.2 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

List of Tables
Table 1 Summary of MPA, Market, Epidemiology, and Key Events (2018-2030)
Table 2 Summary of biomarkers/potential biomarkers in AAV
Table 3 SICVE guidelines Systemic vasculitis Recommendations
Table 4 Induction and maintenance therapies for GPA/MPA
Table 5 Recommendations
Table 6 Total Incident Cases of Microscopic polyangiitis (MPA) in the 7MM (2018-2030)
Table 7 Total Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018-2030)
Table 8 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018-2030)
Table 9 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018-2030)
Table 10 Total Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018-2030)
Table 11 Total Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018-2030)
Table 12 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018-2030)
Table 13 Total Incident Cases of Microscopic polyangiitis (MPA) in France (2018-2030)
Table 14 Gender-specific Total Incident Cases of Microscopic polyangiitis (MPA) in France (2018-2030)
Table 15 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in France (2018-2030)
Table 16 Total Incident Cases of Microscopic polyangiitis (MPA) in Italy (2018-2030)
Table 17 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Italy (2018-2030)
Table 18 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Italy (2018-2030)
Table 19 Total Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018-2030)
Table 20 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018-2030)
Table 21 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018-2030)
Table 22 Total Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018-2030)
Table 23 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018-2030)
Table 24 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018-2030)
Table 25 Total Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018-2030)
Table 26 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018-2030)
Table 27 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018-2030)
Table 28 Organizations contributing toward Microscopic Polyangiitis (MPA)
Table 29 Rituximab, Clinical Trial Description, 2021
Table 30 Comparison of emerging drugs under development
Table 31 Vilobelimab, Clinical Trial Description, 2021
Table 32 Vynpenta (Avacopan, CCX168), Clinical Trial Description, 2021
Table 33 Belimumab, Clinical Trial Description, 2021
Table 34 GGS-MPA, Clinical Trial Description, 2021
Table 35 Seven Major Market Size of Microscopic polyangiitis in USD Million (2018-2030)
Table 36 Seven Major Market Size of Microscopic polyangiitis by Therapies in USD Million (2018-2030)
Table 37 Key market forecast assumptions for Avacopan
Table 38 Key market forecast assumptions for Vilobelimab
Table 39 The United States Market Size of Microscopic polyangiitis in USD Million (2018-2030)
Table 40 The United States Market Size of Microscopic polyangiitis by therapies in USD Million (2018-2030)
Table 41 Germany Market Size of Microscopic polyangiitis in USD Million (2018-2030)
Table 42 Germany Market Size of Microscopic polyangiitis by therapies in USD Million (2018-2030)
Table 43 France Market Size of Microscopic polyangiitisin USD Million (2018-2030)
Table 44 France Market Size of Microscopic polyangiitis by therapies in USD Million (2018-2030)
Table 45 Italy Market Size of Microscopic polyangiitisin USD Million (2018-2030)
Table 46 Italy Market Size of Microscopic polyangiitis by therapies in USD Million (2018-2030)
Table 47 Spain Market Size of Microscopic polyangiitis in USD Million (2018-2030)
Table 48 Spain Market Size of Microscopic polyangiitis by therapies in USD Million (2018-2030)
Table 49 The United Kingdom Market Size of Microscopic polyangiitis in USD Million (2018-2030)
Table 50 The United Kingdom Market Size of Microscopic polyangiitis by therapies in USD Million (2018-2030)
Table 51 Japan Market Size of Microscopic polyangiitis in USD Million (2018-2030)
Table 52 Japan Market Size of Microscopic polyangiitis by therapies in USD Million (2018-2030)

List of Figures
Figure 1 Vasculitis
Figure 2 Microscopic polyangiitis (MPA)
Figure 3 Symptoms of Microscopic polyangiitis (MPA)
Figure 4 Five most common clinical manifestations of MPA
Figure 5 Pathogenesis of MPA
Figure 6 Diagnostic Algorithm for Vasculitis
Figure 7 Diagnostic algorithm of MPA
Figure 8 Algorithm for the treatment of AAV
Figure 9 Total Incident Cases of Microscopic polyangiitis (MPA) in the 7MM (2018-2030)
Figure 10 Total Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018-2030)
Figure 11 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018-2030)
Figure 12 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the United States (2018-2030)
Figure 13 Total Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018-2030)
Figure 14 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018-2030)
Figure 15 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Germany (2018-2030)
Figure 16 Total Incident Cases of Microscopic polyangiitis (MPA) in France (2018-2030)
Figure 17 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in France (2018-2030)
Figure 18 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in France (2018-2030)
Figure 19 Total Incident Cases of Microscopic polyangiitis (MPA) in Italy (2018-2030)
Figure 20 Gender-specific Incident Cases of Microscopic polyangiitis (MPA)in Italy (2018-2030)
Figure 21 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Italy (2018-2030)
Figure 22 Total Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018-2030)
Figure 23 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018-2030)
Figure 24 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Spain (2018-2030)
Figure 25 Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018-2030)
Figure 26 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018-2030)
Figure 27 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in the United Kingdom (2018-2030)
Figure 28 Total Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018-2030)
Figure 29 Gender-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018-2030)
Figure 30 Age-specific Incident Cases of Microscopic polyangiitis (MPA) in Japan (2018-2030)
Figure 31 Patient Journey
Figure 32 Seven Major Market Size of Microscopic polyangiitis in USD Million (2018-2030)
Figure 33 Seven Major Market Size of Microscopic polyangiitis by Therapies in USD Million (2018-2030)
Figure 34 Market Size of Microscopic polyangiitis in the United States, USD Million (2018-2030)
Figure 35 The United States Market Size of MPA by Therapies in USD Million (2018-2030)
Figure 36 Market Size of Microscopic polyangiitis in Germany, USD Million (2018-2030)
Figure 37 Germany Market Size of Microscopic polyangiitis by Therapies in USD Million (2018-2030)
Figure 38 Market Size of Microscopic polyangiitis in France, USD Million (2018-2030)
Figure 39 France Market Size of Microscopic polyangiitis by Therapies in USD Million (2018-2030)
Figure 40 Market Size of Microscopic polyangiitis in Italy, USD Million (2018-2030)
Figure 41 Italy Market Size of Microscopic polyangiitis by Therapies in USD Million (2018-2030)
Figure 42 Market Size of Microscopic polyangiitis in Spain, USD Million (2018-2030)
Figure 43 Spain Market Size of Microscopic polyangiitis by Therapies in USD Million (2018-2030)
Figure 44 Market Size of Microscopic polyangiitis in the United Kingdom, USD Million (2018-2030)
Figure 45 The UK Market Size of Microscopic polyangiitis by Therapies in USD Million (2018-2030)
Figure 46 Market Size of Microscopic polyangiitis in Japan, USD Million (2018-2030)
Figure 47 Japan Market Size of Microscopic polyangiitis by Therapies in USD Million (2018-2030)
Figure 48 Market Drivers
Figure 49 Market Barriers
Figure 50 SWOT Analysis
Figure 51 Unmet Needs

Key Companies
RITUXAN/MABTHERA (RITUXIMAB): GENENTECH, INC. (F. HOFFMANN-LA ROCHE LTD)/ZENYAKU KOGYO
VILOBELIMAB (IFX-1, CACP290): INFLARX GMBH
VYNPENTA (AVACOPAN, CCX168): CHEMOCENTRYX/KISSEI PHARMACEUTICAL/VIFOR PHARMA
BELIMUMAB: GLAXOSMITHKLINE
GGS-MPA (FREEZE-DRIED SULFONATED HUMAN IMMUNOGLOBULIN): TEIJIN PHARMA